双嘧达莫联合厄贝沙坦对IgA肾病的疗效及其安全性分析

Analysis of Dipyridamole Combined with Irbesartan Treatment on IgA Nephropathy and its Safety

目的探究双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性。方法采取回顾性分析方法对遵义医学院第五附属(珠海)医院2013年7月—2016年7月Ig A肾病患者88例资料进行收集分析,随机分为单药组和联合组。单药组采用单纯厄贝沙坦治疗;联合组采用双嘧达莫联合厄贝沙坦治疗。比较两组患者Ig A肾病治疗效果;治疗前后24 h尿蛋白、血肌酐;不良反应发生率。结果联合组患者Ig A肾病治疗效果比单药组高,P<0.05;治疗前两组患者24 h尿蛋白、血肌酐差异不显著,P>0.05;联合组治疗后24 h尿蛋白、血肌酐比单药组好,P<0.05;联合组不良反应发生率和单药组差异不显著,P>0.05。结论双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性良好,可改善肾功能,无明显副作用,值得推广。

Objective To explore the effect of dipyridamole combined with irbesartan on Ig A nephropathy and its safety.Methods Retrospective methods analysis was performed on 88 patients with Ig A nephropathy in our hospital from July 2013 to July 2016,Single drug group were treated with irbesartan treatment; combination group received dipyridamole combined with irbesartan in the treatment of.Comparison of two groups of patients with Ig A nephropathy treatment effect before and after treatment for 24 hours urine protein,serum creatinine.Results The therapeutic effect of the combined group of patients with Ig A nephropathy than the single drug group,P〈0.05; two groups of patients before treatment and 24 hours urine protein,serum creatinine was not significant,P〉0.05; combined treatment group after 24 hours urine protein,serum creatinine than the single drug group,P〈0.05;united group of adverse reaction difference and the rate of single drug group was not significant,P〉0.05.Conclusion Dipyridamole combined with irbesartan treatment on Ig A nephropathy and its safety is good,can improve renal function and no obvious side effects,worthy of promotion.